1-year SELUTION DeNovo results: drug-eluting balloon strategy vs. systematic drug-eluting stent in de novo coronary disease
Reported from TCT 2025
Guillaume Bonnet interviews Christian Spaulding about the SELUTION DeNovo Trial he presented at TCT 2025, in San Francisco.
Prof. Christian Spaulding, principal investigator of the study, discusses the trial design, key outcomes, breaks down the nuances behind the sirolimus DCB strategy versus contemporary DES, and shares insights that go beyond the numbers.
Authors
No comments yet!